REVVITY, INC. 8-K

What Happened Revvity, Inc. (RVTY) filed an 8-K on May 5, 2026 announcing its financial results for the first quarter ended April 5, 2026 and furnished a press release (Exhibit 99.1). The company also provided unaudited pro forma condensed consolidated financial statements (Exhibit 99.2) that reflect the probable sale of substantially all assets of its China Immunodiagnostics business (“China IDX”) under a letter of intent signed April 16, 2026. The LOI contemplates proceeds of up to $200 million, subject to adjustments and customary closing conditions; management believes the transaction is probable and may close in 2027. The filing includes the company’s standard forward‑looking statements caution.

Key Details

• Q1 period reported: quarter ended April 5, 2026; press release filed as Exhibit 99.1 (May 5, 2026).
• LOI dated April 16, 2026 for sale of substantially all China IDX assets for up to $200 million, subject to adjustments and conditions.
• Unaudited pro forma condensed consolidated financial statements included as Exhibit 99.2 to show post‑transaction financial position and results.
• Company notes forward‑looking language and refers investors to its Form 10‑K “Risk Factors”; no assurance transaction will close and timing may be in 2027.

Why It Matters The 8-K provides the company’s latest quarterly results and, importantly, presents how a likely divestiture of China IDX would affect Revvity’s financials. Investors should note the potential one‑time proceeds (up to $200M) and that the pro forma statements are based on management’s view that the sale is probable but not guaranteed—closing depends on conditions and adjustments. The disclosure helps investors assess near‑term cash, asset base, and revenue composition changes if the transaction completes, but actual outcomes and timing remain uncertain.